Allurion Technologies, Inc. 2025 Annual Meeting of Stockholders Summary

Allurion Technologies, Inc. held its 2025 Annual Meeting of Stockholders on December 18, 2025. Key outcomes included the re-election of Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey to the Board of Directors. Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The stockholders approved an amendment and restatement of the 2023 Stock Option and Incentive Plan to increase authorized shares, amend the definition of Fully-Diluted Shares Outstanding, lower the non-employee director compensation limit, and extend the plan's term. Additionally, the repricing of certain outstanding stock options granted under the 2023 Plan was approved. The issuance of common stock upon conversion of Series B Preferred Stock and upon exercise of private placement warrants was also approved to comply with NYSE Listing Rules. Finally, an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split was approved, with the exact ratio to be determined by the Board within a range of 1-for-1.5 to 1-for-20.